Consolidation Radiotherapy
Showing 1 - 25 of 6,013
Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy Trial (Durvalumab + carboplatin/cisplatin + etoposide,
Not yet recruiting
- Lung Cancer
- +2 more
- Durvalumab + carboplatin/cisplatin + etoposide
- +2 more
- (no location specified)
Aug 3, 2022
NSCLC, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation Trial in Beijing (Tislelizumab)
Recruiting
- Non-small Cell Lung Cancer
- +2 more
-
Beijing, ChinaPeking University Cancer Hospital and Institute
Mar 4, 2023
Advanced Prostate Carcinoma, Cancer of Prostate, PSA Trial in Melbourne (Darolutamide, Radiotherapy)
Recruiting
- Advanced Prostate Carcinoma
- +3 more
- Darolutamide
- Radiotherapy
-
Melbourne, Victoria, AustraliaPeter MacCallum Cancer Center
Aug 26, 2021
NSCLC Trial in Ostrava (primary tumour radiotherapy, stereotactic body radiotherapy, maintenance radiotherapy)
Recruiting
- Non-small Cell Lung Cancer
- primary tumour radiotherapy
- +2 more
-
Ostrava, Moravian-Silesian Region, CzechiaUniversity Hospital Ostrava
Dec 6, 2022
Esophageal Tumor Metastatic, Esophageal Cancer Stage IVb Trial in Beijing (drug, biological, radiation)
Recruiting
- Esophageal Neoplasm Metastatic
- Esophageal Cancer Stage IVb
- TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
- +3 more
-
Beijing, Beijing, ChinaCancer hospital, CAMS
Oct 19, 2023
Limited Stage Small Cell Lung Cancer Trial (HLX10, hypofractionated radiotherapy, Prophylactic Cranial Irradiation (PCI))
Not yet recruiting
- Limited Stage Small Cell Lung Cancer
- HLX10
- +2 more
- (no location specified)
Jun 29, 2022
NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)
Recruiting
- Non-small Cell Lung Cancer
- Hypofractionated radiotherapy
- +4 more
-
Guangzhou, Guangdong, ChinaSun yat-sen university cancer center
Nov 14, 2023
HIV, Burkitt's Lymphoma Trial in Italy (Induction Phase, Consolidation Phase (on day +50), Intensification phase)
Completed
- HIV
- Burkitt's Lymphoma
- Induction Phase
- +4 more
-
Aviano (PN), Italy
- +7 more
Aug 2, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, gemcitabin, cisplatin, Stereotactic Body Radiotherapy, Intensity
Recruiting
- Nasopharyngeal Carcinoma
- Camrelizumab, gemcitabin, cisplatin
- Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Jun 19, 2022
Radiotherapy Side Effect, NSCLC, ALK Gene Mutation Trial in Stockholm (SBRT/SRS/radiation therapy)
Not yet recruiting
- Radiotherapy Side Effect
- +2 more
- SBRT/SRS/radiation therapy
-
Stockholm, SwedenKarolinska University Hospital
Feb 16, 2023
Locally Advanced Rectal Carcinoma Trial (Short course radiotherapy with concurrent capecitabine(825mg/m2), Long course
Not yet recruiting
- Locally Advanced Rectal Carcinoma
- Short course radiotherapy with concurrent capecitabine(825mg/m2)
- Long course radiotherapy with concurrent capecitabine(825mg/m2)
- (no location specified)
Jun 24, 2023
Breast Cancer Trial in France, Germany (Intraoperative radiotherapy (IORT))
Active, not recruiting
- Breast Cancer
- Intraoperative radiotherapy (IORT)
-
Montpellier, France
- +3 more
May 30, 2022
Locally Advanced Rectal Cancer Trial in Pisa (drug, radiation, procedure)
Recruiting
- Locally Advanced Rectal Cancer
- Irinotecan
- +5 more
-
Pisa, ItalyU.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Univ
Mar 9, 2022
Locally Advanced Rectal Carcinoma Trial (Cadonilimab Injection, Short-course radiotherapy, Consolidation chemo)
Not yet recruiting
- Locally Advanced Rectal Carcinoma
- Cadonilimab Injection
- +2 more
- (no location specified)
Mar 19, 2023
NSCLC Trial in France (Radiotherapy + durvalumab)
Recruiting
- NSCLC
- Radiotherapy + durvalumab
-
Dijon, France
- +5 more
Mar 25, 2022
Locally Advanced NSCLC, Efficacy and Safety Trial in Guangzhou (Anlotinib, Chemotherapy, Radiotherapy)
Recruiting
- Locally Advanced Non-small Cell Lung Cancer
- Efficacy and Safety
- Anlotinib
- +3 more
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer Center
Jul 28, 2022
Rectal Cancer Trial in New York (Etrumadenant (AB928), Radiation therapy, FOLFOX regimen)
Recruiting
- Rectal Cancer
- Etrumadenant (AB928)
- +3 more
-
New York, New York
- +2 more
Apr 10, 2022
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in United States (biological, procedure,
Recruiting
- Lung Adenocarcinoma
- +2 more
- Ipilimumab
- +5 more
-
Conroe, Texas
- +4 more
May 25, 2022
Stage III NSCLC Trial in Guangzhou (Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy)
Recruiting
- Stage III Non-small Cell Lung Cancer
- Neoadjuvant chemo-immunotherapy
- +5 more
-
Guangzhou, ChinaSun Yat-sen University
Jul 19, 2022
Rectal Cancer Trial in Beijing (drug, radiation, procedure)
Completed
- Rectal Cancer
- Oxaliplatin
- +3 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Jul 21, 2021
Head and Neck Squamous Cell Carcinomas Trial in Guangzhou (Consolidation Toripalimab)
Recruiting
- Head and Neck Squamous Cell Carcinomas
- Consolidation Toripalimab
-
Guangzhou, Guangdong, China
- +1 more
Oct 2, 2021
Stage III Non-small-cell Lung Cancer Trial in Foshan, Guangzhou (other, radiation, drug)
Recruiting
- Stage III Non-small-cell Lung Cancer
- Neoadjuvant therapy
- +4 more
-
Foshan, Guangdong, China
- +2 more
Oct 25, 2022
Rectal Cancer Trial in Warsaw (Radiotherapy boost, Additional consolidation chemo)
Recruiting
- Rectal Cancer
- Radiotherapy boost
- Additional consolidation chemotherapy
-
Warsaw, PolandM. Skłodowska-Curie National Research Institute of Oncology
Feb 4, 2022
NSCLC, Stage III, ALK-rearrangement Trial in Worldwide (Brigatinib, Durvalumab)
Not yet recruiting
- NSCLC, Stage III
- ALK-rearrangement
-
Angers, France
- +19 more
Feb 8, 2023